Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
CAMBRIDGE, Mass. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the BIO CEO &
CAMBRIDGE, Mass. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 7 th Annual
CAMBRIDGE, Mass. , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo , president and CEO, will present the latest
CAMBRIDGE, Mass. and SHANGHAI, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the initiation of its License Agreement with
Facilities Include a $15 Million Term Loan and $10 Million Revolving Line of Credit CAMBRIDGE, Mass. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions,
CAMBRIDGE, Mass. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo , president and CEO, will present the latest
Record Third Quarter Revenue of $14.3 Million Represents a 30% Increase Over Third Quarter 2016 Results Driven by Continued Momentum of MACI Uptake and Expanded Epicel Usage Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation
CAMBRIDGE, Mass., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today provided a general business update during a previously announced webcast
CAMBRIDGE, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the Cell &
